Rejected peptide ads nearly always fail for one reason: the copy speaks to a patient about an outcome. These are the before-and-after rewrites that cleared review, plus reusable headline templates and a banned-word list.
Every compliant rewrite in this category follows one rule: describe the product, never the outcome. Copy fails review when it states or implies what the compound does to a person, and it passes when it stays on attributes the seller can document — the compound, the purity, the testing, the handling, the shipping and the vendor's reliability. Applying that rule mechanically produces predictable rewrites. Outcome headlines become specification headlines. Transformation hooks become documentation hooks. Urgency built on results becomes urgency built on stock or shipping cutoffs. Calls to action point to a research-framed product page rather than a promise. The practical workflow is to run every line against a banned-pattern list before it reaches the platform, because catching a violating phrase in a document costs nothing while catching it in review costs account quality.
Copy that describes the product's documented attributes rather than what it does to a person. Compound, purity, testing, handling, shipping and vendor reliability are all safe subjects; effects and outcomes are not.
Testimonials describing personal results carry the same claim risk as making the claim directly, because platforms attribute the statement to the advertiser. Testimonials about service, shipping and support are a different matter.
Anchor urgency to inventory, batch availability, shipping cutoffs or pricing windows. These are verifiable operational facts rather than implied outcomes.
Anything naming or implying a treated condition, plus dosage guidance, transformation language and phrasing that implies human administration. Screening copy against a maintained banned-pattern list before submission is the practical control.
It converts differently. Removing outcome claims shifts the persuasion burden onto documentation, credibility and operational proof, which is also what separates repeat buyers from one-time buyers.